This point has been extensively explored in several approaches in cancer treatment, such as cancer vaccines against neoantigens and adoptive T cell transfer, which can be combined with immunotherapy targeting T cell inhibitory receptors, including cytotoxic T-lymphocyte associated antigen (CTLA)-4 and programmed cell death (PD)-1 (Peng et al., 2019). Here, PDCD1 is linked to cancer.